Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis: A phase II prospective multicentre study

Pancreatology

Volumn 4, Issue 3-4, 2004, Pages 229-232

  Lévy, Philippe ^a   Hastier, Patrick ^b   Arotçarena, Ramuntcho ^c   Bartolie, Eric ^d   Bougeard Julien, Muriel ^e   Blumberg, Joëlle ^e   O'Toole, Dermot ^a   Ruszniewski, Philippe ^a  

^a BEAUJON HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c CENTRE HOSPITALIER DE PAU   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e IPSEN   (France)

Author keywords

Inhibition of exocrine pancreatic secretion; Necrotizing acute pancreatitis; Pain relapse

Indexed keywords

ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE;

ACUTE HEMORRHAGIC PANCREATITIS; ACUTE PANCREATITIS; ADULT; AGED; ALCOHOLIC PANCREATITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; LENGTH OF STAY; MALE; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFEEDING; RELAPSE; SCORING SYSTEM;

EID: 2942722423     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000078434     Document Type: Article

References (23)

1. Lévy P, Heresbach D, Pariente EA, Boruchowicz A, Delcenserie R, Millat B, Moreau J, Le Bodic L, de Calan L, Barthet M, Sauvanet A, Bernades P: Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: A multivariate multicentre prospective study of 116 patients. Gut 1997;40:262-266.
2. Balthazar EJ, Ranson JH, Naidich DP, Megibow AJ, Caccavale R, Cooper MM: Acute pancreatitis: Prognostic value of CT. Radiology 1985;156:767-772.
3. Heintges T, Luthen R, Niederau C: Inhibition of exocrine pancreatic secretion by somatostatin and its analogues. Digestion 1994;55(suppl 1):1-9.
4. Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S: Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997;43:65-70.
5. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH: Acute pancreatitis: Value of CT in establishing prognosis. Radiology 1990;174:331-336.
6. Banks PA: Practice guidelines in acute pancreatitis. Am J Gastroenterol 1997;92:377-386.
7. Frossard JL, Hadengue A: Pancréatite aiguë: nouvelles données physiopathologiques. Gastroentérol Clin Biol 2001;25:164-176.
8. Uomo G, Molino D, Visconti M, Ragozzino A, Manes G, Rabitti PG: The incidence of main pancreatic duct disruption in severe biliary pancreatitis. Am J Surg 1998;176:49-52.
9. Matsushita K, Okabayashi Y, Hasegawa H, Koide M, Kido Y, Okutani T, Sugimoto Y, Kasuga M: In vitro inhibitory effect of somatostatin on secretin action in exocrine pancreas of rats. Gastroenterology 1993;104:1146-1152.
10. Arnold R, Lankisch PG: Somatostatin and the gastrointestinal tract. Clin Gastroenterol 1980;9:733-753.
11. Williams ST, Woltering EA, O'Dorisio TM, Fletcher WS: Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 1989;157:459-462.
12. Reichlin S: Somatostatin. Part 2. N Engl J Med 1983;309:1556-1563.
13. Reichlin S: Somatostatin. Part 1. N Engl J Med 1983;309:1495-1501.
14. Scarpignato C, Pelosini I: Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety. Digestion 1999;60(suppl 3):1-16.
15. Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, Campbell KA, Choti MA: Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419-429.
16. Pederzoli P, Bassi C, Falconi M, Albrigo R, Vantini I, Micciolo R: Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin. Surg Gynecol Obstet 1986;163:428-432.
17. Falconi M, Contro C, Ballabio M, Bassi C, Salvia R, Pederzoli P: Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: Preliminary study. Dig Liver Dis 2002;34:127-132.
18. Cavallini G, Frulloni L: Somatostatin and octreotide in acute pancreatitis: The never-ending story. Dig Liver Dis 2001;33:192-201.
19. Büchler MW, Binder M, Friess H: Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis. Gut 1994;35:S15-S19.
20. D'Amico D, Favia G, Biasiato R, Casaccia M, Falcone F, Fersini M, Marrano D, Napolitano F, Oliviero S, Rodolico A: The use of somatostatin in acute pancreatitis - Results of a multicenter trial. Hepatogastroenterology 1990;37:92-98.
21. Malfertheiner P, Mayer D, Büchler M, Dominguez-Munoz JE, Schiefer B, Ditschuneit H: Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut 1995;36:450-454.
22. Schmalz M, Soergel K, Johanson J: The effect of octreotide acetate (Sandostatin), on the pain of chronic pancreatitis. Gastroenterology 1992;102(suppl 2):A290.
23. Conférence de consensus: Pancréatite aiguë. Gastroentérol Clin Biol 2001;25:177-192.